SUFU and medulloblastoma: Importantly and in line with our DYRK1B RNAi data, DYRKi treatment of SAG-treated SUFU-positive (WT MB +SAG) and untreated SUFU-depleted (ΔSufu MB) human medulloblastoma cells prevented GLI1 mRNA expression at comparable IC50 concentrations of 1.16 μM and 1.04 μM, respectively (Figure 4C).